article thumbnail

Effects of ICD Leads on Tricuspid Valve and Right Ventricle

American College of Cardiology

What is the effect of a transvenous implantable cardioverter-defibrillator (TV-ICD) on tricuspid regurgitation (TR) severity, and secondarily, on right ventricular (RV) size and function?

article thumbnail

Implanation of Implantable Cardioverter-Defibrillator Leads in the Coronary Venous System

HeartRhythm

The increasing adoption of transcatheter tricuspid valve replacement (TTVR) has underscored the complexities of managing patients with cardiac implantable electronic device (CIED) leads and tricuspid valve (TV) interventions.

article thumbnail

PO-06-008 LEAD EXTRACTION INCREASES TRICUSPID REGURGITATION

HeartRhythm

Severe Tricuspid Regurgitation (TR) is associated with increased mortality. Change in TR severity with transvenous pacemaker (PPM) and implantable cardioverter defibrillator lead extraction has been poorly studied.

article thumbnail

PO-02-187 EFFECT OF PACEMAKER LEAD SIZE ON DEGREE OF TRICUSPID REGURGITATION: A FOCUS ON THE MEDTRONIC MODEL 3830 LEAD

HeartRhythm

Tricuspid regurgitation (TR) is a common valvular disorder with a spectrum of etiologies including mechanical disturbance of the tricuspid valve by catheters, wires, and the presence of a pacemaker or defibrillator.

article thumbnail

Echocardiographic Predictors of Ventricular Arrhythmias in Patients With Left Ventricular Assist Devices and Implantable Cardioverter‐Defibrillator

Journal of Cardiovascular Electrophysiology

All patients demonstrated a significant decrease in LVEDD as well as a reduction in severity of mitral and tricuspid regurgitation during 1 year after LVAD implantation, reflecting left ventricular unloading through the LVAD.

article thumbnail

Evaluation of JVP

All About Cardiovascular System and Disorders

And that will be the approximate level of the tricuspid valve, the reference point for measuring right atrial pressure. In right atrial tracing, this occurs at the time of right ventricular contraction, with bulging upwards of the tricuspid valve. The Y descent is shallow in tricuspid stenosis, and absent in cardiac tamponade.

article thumbnail

2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices 

Cardiometabolic Health Congress

Edwards EVOQUE Tricuspid Valve Replacement System (Approved: 02/01/2024) This system provides a novel approach to tricuspid valve replacement, potentially benefiting patients with tricuspid regurgitation without open-heart surgery. Join us as we examine the landmark approvals that are revolutionizing patient outcomes.